Genprex, Inc. Files 8-K with Office and Contact Updates
Ticker: GNPX · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1595248
Sentiment: neutral
Topics: corporate-filing, contact-information
Related Tickers: GNPX
TL;DR
Genprex updated its official address and contact info in an 8-K filing.
AI Summary
Genprex, Inc. filed an 8-K on November 5, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 3300 Bee Cave Road, #650-227, Austin, TX 78746, and its telephone number as (512) 537-7997. The report covers events as of November 4, 2024.
Why It Matters
This filing provides updated contact and location information for Genprex, Inc., which is important for investors and stakeholders to ensure they have the correct details for communication and official correspondence.
Risk Assessment
Risk Level: low — The filing is a routine update of corporate information and does not contain significant financial or operational news that would immediately impact risk.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- 3300 Bee Cave Road, #650-227, Austin, TX 78746 (location) — Principal executive offices
- (512) 537-7997 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Genprex, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 4, 2024.
Where are Genprex, Inc.'s principal executive offices located?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the telephone number for Genprex, Inc.?
The telephone number for Genprex, Inc. is (512) 537-7997.
On what date was this 8-K report filed?
This 8-K report was filed on November 5, 2024.
What is the state of incorporation for Genprex, Inc.?
Genprex, Inc. is incorporated in Delaware.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-11-05 09:29:40
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $1.00 — iled to maintain a minimum bid price of $1.00 or more for 30 consecutive business day
Filing Documents
- gnpx20241030_8k.htm (8-K) — 26KB
- 0001437749-24-033217.txt ( ) — 155KB
- gnpx-20241104.xsd (EX-101.SCH) — 3KB
- gnpx-20241104_def.xml (EX-101.DEF) — 11KB
- gnpx-20241104_lab.xml (EX-101.LAB) — 15KB
- gnpx-20241104_pre.xml (EX-101.PRE) — 11KB
- gnpx20241030_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 4, 2024, Genprex, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") and the Minimum Bid Price Requirement matter is now closed. The letter was pursuant to a previous letter received on September 26, 2024 from Nasdaq Staff indicating, as previously reported, that the Company was not then in compliance with the Minimum Bid Price Requirement because the Company's common stock, par value $0.001 per share, had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 5, 2024 By: /s/ Ryan Confer Ryan Confer Chief Financial Officer (Principal Financial Officer)